Galapagos Seeks Partner For Recently Acquired Low-Dose Estrogen Product
This article was originally published in The Pink Sheet Daily
Executive Summary
The firm continues its acquisition program with the purchase of ProStrakan’s bone disease unit for a maximum value of $60 million.
You may also be interested in...
Galapagos Pushes Bone and Joint Compounds Toward Phase I Trials
New agents could beat standard of care in bone cancer metastases and rheumatoid arthritis, firm says.
Galapagos Pushes Bone and Joint Compounds Toward Phase I Trials
New agents could beat standard of care in bone cancer metastases and rheumatoid arthritis, firm says.
Wyeth Licenses Osteoporosis Drug Targets From Galapagos
Wyeth agrees to second milestone stemming from 2003 agreement, selecting three novel Galapagos targets for osteoporosis.